Parkinson mice show functional and molecular changes in the gut long before motoric disease onset

Manuela Gries1†, Anne Christmann1†, Steven Schulte1, Maximilian Weyland1, Stephanie Rommel1, Monika Martin1, Marko Baller1, Ralph Röth2, Stefanie Schmitteckert2, Marcus Unger3, Yang Liu3, Frederik Sommer4, Timo Mühlhaus5, Michael Schroda5, Jean-Pierre Timmermans6, Isabel Pintelon6, Gudrun A. Rappold2,7, Markus Britschgi8, Hilal Lashuel9, Michael D. Menger10, Matthias W. Laschke10, Beate Niesler2 and Karl-Herbert Schäfer1,11*

Abstract

Background: There is increasing evidence that Parkinson’s disease (PD) might start in the gut, thus involving and compromising also the enteric nervous system (ENS). At the clinical onset of the disease the majority of dopaminergic neurons in the midbrain is already destroyed, so that the lack of early biomarkers for the disease represents a major challenge for developing timely treatment interventions. Here, we use a transgenic A30P-α-synuclein-overexpressing PD mouse model to identify appropriate candidate markers in the gut before hallmark symptoms begin to manifest.

Methods: Based on a gait analysis and striatal dopamine levels, we defined 2-month-old A30P mice as pre-symptomatic (psA30P), since they are not showing any motoric impairments of the skeletal neuromuscular system and no reduced dopamine levels, but an intestinal α-synuclein pathology. Mice at this particular age were further used to analyze functional and molecular alterations in both, the gastrointestinal tract and the ENS, to identify early pathological changes. We examined the gastrointestinal motility, the molecular composition of the ENS, as well as the expression of regulating miRNAs. Moreover, we applied A30P-α-synuclein challenges in vitro to simulate PD in the ENS.

Results: A retarded gut motility and early molecular dysregulations were found in the myenteric plexus of psA30P mice. We found that i.e. neurofilament light chain, vesicle-associated membrane protein 2 and calbindin 2, together with the miRNAs that regulate them, are significantly altered in the psA30P, thus representing potential biomarkers for early PD. Many of the dysregulated miRNAs found in the psA30P mice are reported to be changed in PD patients as well, either in blood, cerebrospinal fluid or brain tissue. Interestingly, the in vitro approaches delivered similar changes in the ENS cultures as seen in the transgenic animals, thus confirming the data from the mouse model.

(Continued on next page)
Introduction
In Parkinson’s disease (PD), the loss of nigrostriatal dopaminergic neurons causes the hallmark motor symptoms of muscle rigidity, tremor at rest, and bradykinesia [1]. In recent years, early non-motor symptoms of PD have gained attention; these include sleep disturbance, pain, depression, and constipation, and can occur more than 15 years before clinical motor symptoms manifest [2]. Histopathological examination of postmortem PD brains has revealed intraneuronal accumulations of misfolded α-synuclein, termed Lewy bodies [3]. These Lewy bodies disrupt protein ubiquitination, cytoskeleton reorganization, synaptic function and vesicle release, and increase oxidative stress levels to promote PD pathogenesis [4]. Lewy bodies are present not only in the central nervous system (CNS) but also in the enteric nervous system (ENS) of the intestine, so it is not only the brain but also the gut that is involved in PD pathogenesis [5, 6]. In 2003, Braak et al. postulated that neurotoxic α-synucleins may originate in the gut and migrate to the brain via the vagal nerve [7, 8]. This theory was recently supported by studies in animal models [9, 10], which confirmed that α-synuclein transport can be purged by vagal nerve resection [11, 12]. Previous research has shown that the crosstalk between the gut and the brain during PD pathogenesis is mainly influenced by intestinal dysbiosis [13, 14]. This suggests that the gastrointestinal (GI) motility deficits associated with PD, such as constipation, are caused by alterations in the microbial composition of the gut, which disrupt gut microbiome and gut-brain-axis may homeostasis and increase inflammation and permeability of the gut [14–17]. These findings indicate that PD originates in the gut, and that a dysregulated gut contributes to PD symptoms. However, changes in the ENS during PD onset have not been well-described. To better understand the role of the gut in PD, a more detailed investigation of the early phase of PD within the gut is essential. The current study aimed to assess early pathological changes associated with PD in the ENS to identify biomarkers of pre-clinical PD. In recent years, miRNAs have emerged as important regulators of gene expression, cell differentiation, cell maturation, apoptosis, and immune responses [18]. They are present in circulating body fluids [19] as well as gut mucosal tissues, so they can be investigated by colonoscopy [20]. Abnormal miRNA expression has been linked to many human diseases, and miRNAs have been identified as diagnostic and prognostic biomarkers for several disorders, including PD [21, 22]. However, no PD-specific miRNAs have been identified in the gut for the pre-clinical diagnosis of PD so far [23, 24]. To address this, we studied functional and molecular changes in ENS of A30P mice before onset of PD symptoms to identify gut-related biomarkers for early stages of PD.

Methods
Animals
α-synuclein-overexpressing transgenic A30P mice (Thy-1-SNCA-A30P [25]), based on a genetic C57B6/J background and age- and sex-matched wild type (WT) mice (postnatal day 2, adult 2 months and 12–13 months old) were used in experiments. Two-month-old A30P mice were defined as pre-symptomatic (ps)A30P mice and were used in experiments. Two-month-old A30P mice were used as pre-symptomatic (ps)A30P mice and were used in expression profiling experiments. Animals were housed under specific pathogen-free conditions on a 12 h light/12 h dark cycle according to German regulations. For tissue dissections, adult mice were deeply anesthetized with isoflurane (Piramal Critical Care) and sacrificed by inhalation of an overdose. Newborn mice were killed by decapitation. Animals were dissected according to the guidelines of the local ethics committee and in accordance with the animal protection laws in Rhineland-Palatinate, Germany.

Gait analysis
Gait was assessed in adult A30P and WT mice (2 months and 12–13 months old) using the Noldus CatWalk XT software. For each experiment, a minimum training period of five runs the day before the experimental run. Mice that failed the training were excluded from the study. Footprints were classified automatically as right forepaw, right hindpaw, left forepaw, and left hindpaw. For each experiment, correct paw labels and footfall patterns were controlled, followed by an automated analysis of wide-range parameters involving spatial and temporal characteristics. After the gait...
analysis, the small intestine (SI) and the large intestine (LI) of 2-month-old and 12–13-month-old A30P and WT mice were removed and the gut lengths were measured.

**Tissue preparation**

SI and/or LI segments from psA30P and WT mice (2 months, 12–13 months old and/or newborn) were collected in MEM-Hepes + 100 U/ml pencillin/100 μg/ml streptomycin (P/S) and the mesentery was removed. For full-thickness intestinal wall and whole-muscle layer preparations from adult mice, the segments were flushed with MEM-Hepes + 1% P/S to remove feces, followed by muscle layer dissection. Parts of the intestines were used to isolate the myenteric plexus (MP) for further studies. Brains were removed completely and dissected and processed appropriately.

**Isolation of the MP**

Primary enteric cells, in particular MP from newborn and adult mice, were isolated as previously described [26, 27]. In brief, stripped muscle layers were cut into small pieces and digested with 0.375 mg/ml Liberase (Roche) and 0.2 mg/ml DNase (Roche) in Hanks’ balanced salt solution. Adult SI was incubated at 37 °C for 4 h and adult LI for 4.5 h. Thereafter, purified MP networks were washed twice with 0.01 M phosphate-buffered saline (PBS), frozen in liquid nitrogen, and stored at −80 °C for further experiments. Tissue from newborn C57B6/J mice was digested for 2.5 h and MP cells were dissociated for cell culture experiments by incubation with TrypLE (Gibco) (2 x 6 min at 37 °C) and triturated into a single-cell suspension with 23G and 27G needles.

**Isolation of the mesencephalon and the striatum**

The mesencephalon was also isolated from psA30P and WT mice along with the MP. The brain was separated from the skin and the skull, and placed dorsal side up. The mesencephalon was dissected using a scalpel blade. A first cut was made adjacent to the inferior colliculi, followed by a second cut of approximately 4 mm in a rostral direction. The slice was placed with the rostral side up and the mesencephalon was taken out without including the hippocampus, cortex, or cerebellum. To dissect the striatum, the whole brain was sliced frontally in 2 mm sections, using a carbon steel razor blade. From the section where the striatum was easily to identify, the striatum was dissected with a fine tipped microscalpel. Both, the mesencephalon and the striatum were snap-frozen with liquid nitrogen and stored at −80 °C for further experiments.

**Whole-mount preparations**

Segments of full-thickness intestinal wall and the outer muscle layer of psA30P and WT mice were stretched flat and fixed on a Sylgard plate followed by fixation with 4% paraformaldehyde for 2 h at 4 °C. Afterwards, samples were washed three times with PBS for 10 min. Intestinal wall samples were cut into 1 cm pieces, the muscle layers were removed, and samples were stored in 0.1% NaN3 in PBS at 4 °C for further experiments.

**Dopamine ELISA**

Total dopamine levels in the striatum of A30P and C57B6/J mice (2 months and 12–13 months old) were quantified using a chemiluminescent enzyme-linked immunosorbent assay (ELISA) dopamine kit (enzolife-sciences) according to the manufacturer’s instructions. 50 μl of each diluted (1:10 in 0.01 M PBS) homogenized sample was used for the ELISA analysis. Based on a standard curve absolute dopamine values were determined, while only samples within the detection range were used. To obtain the final dopamine content in the sample, the used tissue and buffer volumes were factored in as dilutions.

**Paraffin immunofluorescence (IF-P)**

For Paraffin Immunofluorescence the gut tissues were fixed overnight with 4% formalin, dehydrated in a graded rising alcohol series (70, 80, 90 and 100%, each 2x3min) and embedded in paraffin wax. The paraffin embedded tissues were cut into 5 μm slides (cross sections) and stored at 4 °C.

Paraffin sections were deparaffinized in xylene substitute (3x10min), and a graded series of descending alcohol (100, 90, 80 and 70%, each 2x3min), followed by distilled water (2x3min) and TBST (5 min, 0.025% Triton-X-100 in TBS). For antigen retrieval sections were incubated with 0.01 M citric acid (pH = 6.1) for 30 min using a steamer. Cooled down sections were rinsed twice in TBST (0.025% Triton-X-100 in TBS) for 5 min and blocked in 10% normal serum with 1% BSA in TBS for 2 h at RT. Then primary antibodies (Supplementary Table 1), diluted in TBS with 1% BSA, were applied and incubated overnight at 4 °C. Again, samples were rinsed in TBST (0.025% Triton-X-100 in TBS) for 5 min before the secondary antibodies (Supplementary Table 1), diluted in TBS with 1% BSA, were added and incubated for 1 h at RT. After washing three times for 5 min in TBS sections were mounted with fluorescent mounting medium.

**GI motility recordings**

Video recording with spatiotemporal mapping is a reliable technique for monitoring and displaying motility of gut segments. To evaluate GI motility in psA30P and
WT mice, a luminal perfusion setup was used as previously described by Schreiber et al. 2014 [28]. In brief, a 3.5-cm gut segment of the ileum and proximal LI were dissected and the mesentery was removed. Then, the tissue was fixed on Luer locks in an organ bath filled with tyrode buffer (130 mM NaCl, 24.2 mM NaHCO$_3$, 11 mM glucose, 4.5 mM KCl, 2.2 mM CaCl$_2$, 1.2 mM NaH$_2$PO$_4$, 0.6 mM MgCl$_2$), gassed with carbogen to reach a stable physiological pH 7.4. The perfusion bath was kept at 37 °C using a heat exchanger. Intestinal segments were luminafused at a flow rate of 0.2 ml/min while the height of the luminal efflux tubing relative to the water level (3 cm) was set to a corresponding luminal pressure. All preparations were allowed to equilibrate for 10 min followed by a 10 min spontaneous motility period.

GI motility was assessed by video recordings at 25 frames/s. Videos were analyzed and quantified by MotMap (www.smoothmap.org) and a custom written LabVIEW program (LabVIEW 2019, National Instruments). The video analysis software MotMap was used to set 30 imaginary dots along a 2 cm gut segment on the lower and upper border of the gut as seen in Fig. 3a. The up and down movements of these dot pairs were tracked automatically to calculate the positions to each other for every frame, representing the amplitude of gut activity (Δ). Before the analysis, the program automatically applies a low frequency baseline correction to each of the 30 sections to compensate for slow gut movements. To validate amplitude changes, all values were normalized to their initial diameter. The motility data represent dilatations as positive values vs. the average diameter and contractions as negative values. Motility was converted to high-resolution spatiotemporal heatmaps, while all values were specified in a color range using the custom written LabVIEW software. Gut contractions were counted using spatiotemporal heatmaps. The mean interval was defined as the duration of one contraction and one dilatation (Fig. 3a) and indicated the corresponding frequency. The contraction duration was calculated as the time between adjacent leading edge to leading edge zero crossings. To suppress a noise-induced false triggering, a hysteresis threshold was set at the order of 0.05 to 0.1 mm. Each of the 30 dots over the 2 cm was separately analyzed by determining the duration of all full cycles followed by averaging over all detected cycle durations. To determine the velocity of GI motility, slopes of individual contractions were measured in the LabView program by manually aligning a cursor over the wave top, as shown in Fig. 3b. The program calculates the velocity from the start and end point of the cursor. Together, mean intervals, contraction numbers, and contraction velocity provide information about peristaltic activity.

### Protein isolation for mass spectroscopy of the MP

Protein profiles of purified MP from SI and LI tissue obtained from psA30P and WT mice were investigated by mass spectroscopy. Harvested MP networks were thawed and transferred into 0.1 μM PBS, containing 1:100 protease inhibitor (Roche) and nuclease mix (GE Healthcare), and were vortexed. After five freeze-thaw cycles in liquid nitrogen, samples were purified with the 2-D Clean up kit (GE Healthcare). Pelleted proteins were resuspended in 6 M urea, 2 M thiourea and 25 mM NH$_4$HCO$_3$ at pH 8. The protein concentration was measured using the 2-D Quant kit (GE Healthcare). A total protein amount of approximately 16 μg for the colon and 25 μg for the small intestine was determined.

Mass spectrometry analysis was performed on a high-resolution LC-MS system (Eksigent nanoLC 425 coupled to a Triple-TOF 6600, AB Sciex) in information-dependent acquisition (IDA) mode. HPLC separation was performed in trap-elution mode using a Symmetry C18 column (5 μm particles, 0.18 × 20 mm, Waters) for trapping and a self-packed analytical column (75 μm × 150 mm, 3 μm particles ReproSil-PurC18-AQ) for separation. A constant flow of 300 nl/min was used and the gradient was ramped within 108 min from 2 to 33% of HPLC buffer B (buffer A: 2% acetonitrile, 0.1% formic acid; buffer B: 90% acetonitrile, 0.1% formic acid), then within 12 min to 50% buffer B, followed by washing and equilibration steps. The mass spectrometer was run in IDA mode and recorded one survey scan (250 ms, 350–1500 m/z) and fragment spectra (70 ms, 100–1400 m/z) of the 25 most intense parent ions (charge state >2, intensity > 300 cps, exclusion for 15 s after one occurrence), giving a cycle time of 2 s. In total, 1044 different proteins were investigated (Supplementary Table 2).

In the mass spectrometry-based proteomics workflow followed here, the quantification of proteins depends on the integration of quantitative information from several independent tryptic peptides, which is derived from extracted ion chromatograms (XICs) obtained for each peptide at the MS1 level. The quantitative information derived is very reliable and more robust compared with western blotting. We have demonstrated this recently by comparing MS-based quantification with quantification by western blots, where quantified changes were the same, but MS-based quantification was associated with less variance [29]. Hence, using a more inaccurate method to validate a more accurate one seems counterintuitive.

The yielded proteins were then analyzed and visualized by Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) and Ingenuity Pathway Analysis (IPA) software tool (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis).
Whole-mount immunostaining

Immunostaining and clearing procedures for the full-thickness intestinal wall and muscle layer samples were performed as previously described [30]. In brief, whole-mount muscle layer and intestinal wall preparations of LI specimens from psA30P mice and corresponding WT were permeabilized for 4 h at 37 °C on a shaker with permeabilization solution (0.01% NaN₃ + 1% normal donkey serum + 1% Triton-X-100 in PBS). Then, samples were blocked in blocking solution (0.01% NaN₃ + 10% normal donkey serum + 0.1% BSA + 1% Triton-X-100 in PBS) for 4 h at room temperature (RT) on a shaker. Subsequently, samples were incubated with primary antibodies (diluted in blocking solution, Supplementary Table 1) at 37 °C for 48 h using an orbital shaker. After rinsing four times in PBST (0.05% Tween20 in PBS) for 30 min, tissues were incubated with respective secondary antibodies (1:500 in 0.01% NaN₃ + 1% Triton-X-100 in PBS) overnight at 37 °C on an orbital shaker (Supplementary Table 1). Again, samples were rinsed with PBST four times for 30 min and then counterstained with DAPI (1:1000) for 2 h at RT. Samples were washed in PBS five times for 10 min at RT. For the clearing procedure, Histodenz (Sigma) was diluted with melted N-methylacetamide (40% in PBS, Sigma) to 86% (w/v) concentration and incubated at 37 °C until dissolved. Then 0.1% Triton-X-100 and 0.5% 1-thioglycerol were added to the clearing solution. After being incubated in completed clearing solution for 1–5 min, the outer muscle layers were mounted in fluorescent mounting medium. Detection and image processing were performed with CellObserver Z1 using the ApoTome technology and Axiovision software (Zeiss). The quantification of the immunofluorescence images was performed using ImageJ software. To quantify the expression per picture section, fluorescence images were converted to binary pictures, where the immunostained areas were presented in white and the percentage of positive area per picture section was calculated.

Full-thickness samples were incubated in completed clearing solution overnight and imaged on a Leica SP8 confocal microscope (Leica Microsystems CMS GmbH, Germany). For imaging, samples were positioned in a glass-bottomed petri dish, submerged in the clearing solution and covered by a golden ring with nylon mesh to prevent the tissue from floating. 3-D renderings from intestinal wall samples were obtained using the 3-D Viewer of the Leica LAS X software (Leica microsystems, Wetzlar, Germany).

In vitro studies

Aggregation of A30P α-synuclein

The A30P α-synuclein (kindly provided by Hilal Lashuel) was purified by size exclusion chromatography followed by reverse phase chromatography, which ensures removal of endotoxins. To create aggregated α-synuclein peptides, 50 μM of endotoxin free A30P α-synuclein and 50 μM dopamine (Sigma) were diluted in 5 mM Tris-HCl with 100 mM NaCl at pH 7.4 using low protein binding tubes. The aggregation process was enforced by permanent shaking for 3 days at 37 °C as previously described [31].

Cell treatment with A30P α-synuclein

Dissociated MP cells from newborn mice were plated on extracellular matrix (ECM) (Sigma)-coated coverslips (40,000 cells/coverslip). Cells were maintained for 7 days in differentiation medium consisting of DMEM/F-12 medium, 1% bovine serum albumin (BSA), 2% B27 with retinoic acid supplement, 0.1% β-mercaptoethanol, P/S and 10 ng/μl human glial cell-derived neurotrophic factor (Immuno Tools) before exposure to monomeric and aggregated A30P α-synuclein. Culture medium was replaced by medium with B27 without antioxidants, containing 0.5 μM A30P α-synuclein in Tris-HCl. After α-synuclein treatment for an additional 5 days, cells were fixed with 4% formaldehyde for 15 min at RT and were washed 3 times with 0.01 M PBS. To determine cell viability after α-synuclein treatment, a live-dead-assay was performed. Cells were incubated with 1 μg/ml calcein and 0.5 μg/ml propidiumiodide in 0.01 M PBS for 15 min at 37 °C and analyzed with the CellObserver Z1 and Axiovision software (Zeiss). Total numbers of living and dead cells were calculated per picture section.

Immunocytochemistry

Cells were fixed with 4% formaldehyde and permeabilized with 0.1% Triton-X-100 for 10 min, followed by 30 min blocking in 0.01 M PBS with 10% normal donkey serum. Primary antibody incubation (Supplementary Table 1) was performed for 1 h at RT in 0.01 M PBS. Samples were washed three times in PBS and further incubated with respective secondary antibodies (1:500, Supplementary Table 1) in 0.01 M PBS for 1 h at RT. Samples were washed three times in PBS and once in distilled water. Cells were then mounted on slides with fluorescent mounting medium with DAPI. Detection and image processing were performed with CellObserver Z1 using the ApoTome technology and Axiovision software (Zeiss). To determine the ratios of Nefl and Calb2 positive cells to the total number of neurons, numbers of cells positive for each protein were manually counted and divided by the number of PGP9.5 positive neurons.

nCounter analysis

For miRNA profiling, total RNA (including small RNAs) from the MP of the LI and the mesencephalon samples from psA30P and WT mice was isolated with the miRNeasy
Micro Kit (Qiagen). RNA was eluted in 10 µl (50–100 ng/µl) nuclease-free H2O. RNA quantity and quality were assessed using the Qubit® 4 Fluorometer (Qubit RNA HS Kit; Invitrogen) and the NanoDrop 2000 (Thermo Fisher Scientific). Agilent Bioanalyzer 2100 (TotalRNA Nanokit) and miRNA profiling was performed using the nCounter SPRINT system (NanoString Technologies, USA, www.nanostring.com) at the nCounter Core Facility of the University of Heidelberg (Heidelberg, Germany, www.ncounter.uni-hd.de). For miRNA library preparation and subsequent probe hybridization using the mouse miRNA panel 1.5 (Supplementary Table 3), 100 ng of total RNA was applied. Using the standard nCounter miRNA assay protocol, expression profiles of 578 mouse miRNAs derived from miRbase v.22 were determined. Only miRNAs with at least 100 counts were considered as robustly expressed and included in differential expression analysis of psA30P vs. WT tissue. Data were analyzed using the nSolver software version 4.0 (NanoString Technologies). Stably expressed housekeeping genes such as beta-actin (Actb), beta-2-microglobulin (B2m), glyceraldehyde 3-phosphate dehydrogenase (Gapdh), and ribosomal protein L19 (Rpl19) were used for data normalization. To investigate a potential impact of the dysregulated miRNAs on target gene translation, the top-regulated miRNAs were subjected to target gene prediction using mirWALK 3.0 integrating the algorithms of multiple miRNA target prediction tools [32].

To gain further insight into the function of the most dysregulated miRNAs and their targets, data were put into biological context using the knowledge-based IPA. IPA integrates selected data sets (in our case, miRNA profiles and proteomics) with mining techniques to predict functional connections, protein networks, protein-protein interactions, and related biological functions as well as canonical signaling pathways. miRNA target filter plus miRNA/target = protein pairing analysis were used to identify co-regulated miRNA/target mRNA pairs.

Statistical analyses
For statistical analysis, GraphPad Prism Software 8 was used. Normality of the sample populations was tested with the Shapiro-Wilk test. For normally distributed data, group differences were analyzed with the Student’s t-test and the associated effect sizes with the Cohen’s test [33] or two-way ANOVA. Data are displayed as means ± SD and p-values ≤ 0.05 (*), ≤ 0.01 (**) and ≤ 0.001 (***) were considered statistically significant.

Results
2-month-old A30P mice are pre-symptomatic (psA30P mice)
Gait analysis has been used to show onset of obvious PD manifestations in mice [34]. We analyzed ten gait parameters of A30P and wild type (WT) mice using the CatWalk XT system. Animal footprints were automatically captured by the video camera of the system and were further categorized into individual paws like right forepaw (RF), right hindpaw (RH), left forepaw (LF), and left hindpaw (LH) via the software (Fig. 1a). To characterize pre-symptomatic PD or phenotype-manifested PD in mice, we assessed the gait in two age groups: 2 months old and 12–13 months old. Body mass was not different between 2-month-old A30P and WT mice, but 12–13-month-old A30P mice were significantly heavier than age-matched WT mice (Supplementary Fig. 1). As expected, the older A30P mice showed significant motor impairments in all tested parameters compared to age-matched controls: maximum contact area, terminal dual stance, body speed, body speed variation, run maximum variation (p ≤ 0.05, Fig. 1b and Supplementary Fig. 2), base of support on front paws (Fig. 1c), run duration (Fig. 1d), average speed (Fig. 1e) and cadence (Fig. 1f). In addition, the older mouse group displayed significantly extended stands (p ≤ 0.05, Fig. 1g–j) and markedly changed footprint patterns from all paws (Fig. 1k–n). In contrast, younger A30P mice showed no significant changes in all investigated gait parameters compared with age-matched WT mice, indicating that these mice have a pre-symptomatic stage of the disease. We also measured gut length in these mice. Gut length did not differ between A30P and WT mice in both age groups, but both intestines were significantly longer in 12–13-month-old A30P and WT mice compared with 2-month-old A30P and WT mice (Supplementary Fig. 3).

To proof that 2-month-old A30P mice do not show a significant PD pathology in the brain yet, we assessed striatal dopamine levels of 2-month-old and 12–13-month-old A30P and WT mice. Therefore, we isolated the striatum of these mice and measured the dopamine content using an ELISA (Fig. 2a). In the suspected pre-symptomatic PD group (2 months old) we found no significantly altered dopamine levels (475,23 pg ± 100,78) compared with the corresponding WT (525,67 pg ± 57, 27), revealing no significant brain pathology at this time point. The older A30P group instead, which also shows motoric impairments in the CatWalk, displays significantly reduced striatal dopamine levels (165,40 pg ± 64, 65; p ≤ 0.01) compared with the age-matched WT group (332,38 pg ± 27,46) indicating a diseased brain.

But to give evidence for a pre-manifestation of PD in the gut in the 2-month-old mice, we identified disease causing overexpressed α-synuclein aggregates (human A30P α-synuclein) in the small and the large intestine of both, 2-month-old PD and WT mice, using Paraffin immunofluorescence. We were able to detect overexpressed human α-synuclein aggregates in the SI (Fig. 2c) as well as in the LI (Fig. 2e) of A30P mice. Interestingly,
the expression level is less prominent in the SI, while in the WT mice no human α-synuclein could be found in both intestines (Fig. 2b, d).

Based on these findings, the non-motor-impaired 2-month-old PD group with intestinal but no brain α-synuclein pathology, was defined as the pre-symptomatic A30P mouse group (psA30P), and was used for further investigations.

Altered GI motility in psA30P mice
To investigate the hypothesis that the gut is the first site of PD manifestation, we compared GI motility patterns in the SI and the LI of psA30P mice and age-matched WT animals in isolated gut segments. We measured GI movement using several parameters, including changes in amplitude (Δ amplitude), number of contractions, mean interval (Fig. 3a), and velocity of motions (Fig. 3b).

Both, the SI and the LI, had an isochronous motility pattern in WT mice (SI: Fig. 3c,d; LI: Fig. 3j,k), whereas psA30P mice showed a discontinuous outline with extended passive interphases (SI: Fig. 3e,f; LI: Fig. 3l,m). Two-month-old A30P mice showed no motoric changes, which was confirmed by 2-D maps. WT mice are shown in blue (n=4), A30P mice in red (n=5). 2-D maps determine the gait sequence of paw contact with the glass plate over time. * p ≤ 0.05, ** p ≤ 0.01, and *** p ≤ 0.001 using ANOVA.
In the LI, WT mice exhibited 9.5 ± 2.4 contractions (Fig. 3n) with an appropriate velocity of 0.9 ± 0.4 mm/s (Fig. 3o) over a 10-min period. The number (5.3 ± 2.6 contractions per 10 min; \( p \leq 0.05 \), Fig. 3n) and velocity of contractions (0.3 ± 0.1 mm/s; \( p \leq 0.01 \), Fig. 3o) were significantly lower in psA30P mice. In addition, the mean interval was significantly shorter in WT mice (69.1 ± 10.8 s) compared with in psA30P mice (104.4 ± 33.4 s; \( p \leq 0.05 \), Fig. 3p).

The reduced gut motility in psA30P mice can be visualized in the video recordings (Supplementary Videos 1, 2, 3, 4); these videos show retarded activity, slower contractions, and longer static phases in psA30P mice compared with WT mice (Fig. 3).

**Dysregulated protein expressions in the ENS of psA30P mice**

To investigate the role of the ENS in PD pathogenesis, we dissected the myenteric plexus (MP) of the SI and the LI in psA30P and WT mice. Whole protein was isolated from the gut tissue, separated by high-performance liquid chromatography (HPLC), and further analyzed by mass spectroscopy.
The MP protein expression profile was different between psA30P and corresponding WT mice in the SI (Fig. 4a) and LI (Fig. 4b). In total, 1044 proteins were detected by mass spectroscopy; in 7% of proteins, expression was significantly altered in the SI (Fig. 4a, Supplementary Fig. 4a, Supplementary Table 2) and almost twice as many proteins (14%) in the LI (Fig. 4b, Supplementary Fig. 4b and Supplementary Table 2), indicating a stronger and maybe even an earlier manifestation of PD at this anatomical site. Proteins with significant changes in expression were analyzed and visualized by Search Tool for the Retrieval of Interacting Genes/Proteins (STRING). Each dot represents a single protein, while clustered proteins or proteins in the direct neighborhood indicate a similar function (Fig. 4c and d; Supplementary Fig. 4).

We used a Venn diagram to illustrate the distribution of dysregulated proteins in the SI (74 proteins) and the LI (147 proteins); 13 proteins were differentially expressed in both tissues (Fig. 4e). Categorization into groups by the STRING database yielded six different functional clusters: actin and microtubule organization, vesicle transport, calcium binding, ubiquitination, and response to oxidative stress (Fig. 4f). Proteins in these groups are known to be involved in PD pathogenesis in mice and humans, mainly affecting the CNS [35–55].

This functional classification emphasized that more proteins are dysregulated in the LI than in the SI. Therefore,
we focused all further investigations on the LI. We selected three proteins with altered expression for detailed examinations: neurofilament light chain (Nefl), vesicle-associated membrane protein 2 (Vamp2), and calbindin 2 (Calb2). We chose these proteins because they have already been implicated in PD pathology. For example,
Nefl [56–58] and Calb2 [59–62] expression is altered in the brain of humans with PD as well as in PD models, but nothing is known about how these proteins are affected in the gut during early stages of PD. In addition, both, Nefl and Calb2 can co-localize with α-synuclein [63, 64]. Several studies have shown a role for Vamp2 in neurodegeneration [44, 46, 48, 65, 66], but no direct link to PD pathogenesis has been described to date, although Vamp2 does bind to α-synuclein [67].

**Differential Nefl, Calb2, and Vamp2 expression in the ENS of psA30P mice**

To evaluate the expression of Nefl, Calb2, and Vamp2 in the LI during pre-symptomatic early-onset PD, we performed immunohistochemical stains on whole-mounts of the LI from psA30P and WT mice (Fig. 5). Based on our proteomic data and because of their pivotal role in the ENS, we decided to see whether these proteins can serve as biomarkers for early PD. Preliminary assessments of the LI whole-mounts showed a significantly smaller ganglionic area in psA30P mice than in WT mice (Supplementary Fig. 5).

Nefl staining revealed a large number of myenteric ganglia that were evenly distributed over the underlying circular muscle layer. Nefl-positive cells were also frequently encountered in the interconnecting strands running parallel to the circular muscle layer. These fibers had a thinner and smoother morphology than those running longitudinally. In general, Nefl expression was weaker in psA30P mice (8.4 ± 0.8%) than in WT mice (18.3 ± 4.2%; p ≤ 0.01, Fig. 5b). Calb2 showed a prominent immunoreactivity in the cytoplasm of neuronal soma and in axonal projections in both, psA30P and WT mice. However, there was a significantly higher Calb2 expression in WT mice (8.8 ± 1.5%) than in psA30P mice (4.2 ± 0.86%; p ≤ 0.001, Fig. 5c). Calb2 is expressed not only in the MP, but also in the submucosal plexus, which is located in the submucosal layer. Therefore, we imaged the whole gut in 3-D to include both plexuses, and confirmed the reduced Calb2 expression in psA30P mice (Fig. 5d).

Differential Nefl, Calb2, and Vamp2 expression in primary ENS cells from an in vitro PD model

To verify the dose-dependent toxicity of the mutant A30P α-synuclein protein on primary MP cells, we performed a live-dead assay as a pilot experiment with different incubation times (not shown) using MP cells from postnatal C57B6/J mice which were treated with endotoxin-free monomeric and aggregated A30P α-synuclein. Based on these results, we chose a concentration of 0.5 μM for the A30P α-synuclein, and an incubation time of 5 days for further experiments. A30P α-synuclein administration lead to a significantly increased number of dead cells for both (Fig. 6a), the monomeric (163.20 cells ±37.54) and the aggregated form (75.32 cells ±35.52), while this reduction was much more severe when enteric cells were exposed to the aggregated form (reduction monomer: 38.83%, reduction aggregate: 71.77%) compared with the dopamine control (266.77 cells ±59.38) (Fig. 6a).

To quantify the total number of neurons after A30P α-synuclein treatment, cultivated cells were stained with the neuronal marker protein gene product (PGP) 9.5 (Fig. 6b, c). The amount of neurons was significantly reduced (18.43%) after addition of monomeric A30P α-synuclein (WT: 203.54 ± 15.60 PGP9.5-positive cells; monomeric A30P: 166.02 ± 26.06 PGP9.5-positive cells; p ≤ 0.05, Fig. 6b,c) and even more significantly decreased (39.23%) when exposed to the aggregated A30P α-synuclein form (123.69 ± 17.43 PGP9.5-positive cells; p ≤ 0.001, Fig. 6b,c). To further analyze the cellular effects of the more damaging aggregated form of A30P α-synuclein on the expression of neuronal subtypes and synaptogenesis, additional immunocytochemical stainings were performed for class III beta tubulin (TuJ1), Nefl, Calb2, and Vamp2. The same picture as for PGP9.5. appears with the Nefl stainings, where we found significantly fewer Nefl-positive cells (WT: 0.08 ± 0.02 ratio Nefl/PGP9.5; A30P: 0.06 ± 0.01 ratio Nefl/PGP9.5; p ≤ 0.05, Fig. 6d and Supplementary Fig. 6a). An examination of synaptic vesicles revealed significantly less Vamp2-positive signals for aggregated A30P α-synuclein-treated cells per neuronal area (WT: 53.7 ± 11.1%; A30P: 24.7 ± 5.4%; p ≤ 0.01, Fig. 6e). Conversely, we found nearly twice as many Calb2-positive neurons in α-synuclein-aggregate-treated cells compared with the unchallenged cultures (ratio Calb2/PGP9.5 WT: 0.09 ± 0.01; A30P: 0.2 ± 0.06, p ≤ 0.01, Fig. 6f and Supplementary Fig. 6b), which might reflect the described higher resistance of calbindinergic neurons to toxic impacts [68].

**psA30P mice exhibit increased oxidative stress**

In order to determine the oxidative stress levels in psA30P mice we immunostained whole-mount muscle layers of psA0P mice and corresponding WT with malondialdehyde (MDA), a marker for lipid peroxidation representing oxidative stress, along with 4′,6-Diamidino-2-phenylindol (DAPI), and PGP 9.5. As illustrated in Fig. 7, there was no oxidative stress in terms of lipid peroxidation present in the WT (Fig. 7a,c), neither in the SI nor in the LI. In contrary, an increased expression of lipid aldehydes was located in the ENS ganglia in both, the SI (Fig. 7b) and the LI (Fig. 7d), respectively, giving evidence for oxidative stress in the gut of psA30P mice.
Dysregulated miRNA expression in the ENS of psA30P mice

To provide further knowledge into gene expression and regulation of pathologic pathways in the ENS during PD, we evaluated the possible regulating role of miRNAs. Therefore, total RNA was isolated from the MP of the LI and the mesencephalon, and was used to profile the miRNA spectrum in psA30P and WT mice by means of a NanoString nCounter® mouse expression assay (Supplementary Table 3). Individual Volcano plots were applied to identify differentially expressed miRNAs with statistically significance. As presented in the volcano plots, we found 166 robustly expressed miRNAs (more than 100 counts) in the MP of the LI in psA30P mice (Fig. 8a) and 210 miRNAs in the mesencephalon (Fig. 8b) compared with WT mice (Supplementary Tables 4 and 5). This dysregulation was statistically significant for 45 miRNAs in the MP (Fig. 8a), and for only eight miRNAs in the mesencephalon (Fig. 8b). Three miRNAs (miRNA-22, miRNA-140 and miRNA-350) were differentially expressed in both...
The top ten regulated miRNAs in the MP of the LI with the highest fold change and the lowest p-value were following miRNAs: miRNA-19a, 126-3p, 126-5p, 136-5p, 146a-5p, 210-3p, 301a-3p, 338-3p, 377-3p, and 1937c (Supplementary Fig. 7 and Fig. 8a). In the MP of the LI we observed various significant expression changes for miRNAs that target Nefl, Vamp2, and Calb2, supporting our idea that these proteins are potential biomarkers for early-stage PD. Detailed examination of protein-miRNA interactions revealed significant changes in the expression of these proteins.
clustering using mirWALK 3.0 [32] revealed that Nefl (Fig. 8d, pink framed boxes) and Vamp2 (Fig. 8d, blue framed boxes) are both targeted by ten miRNAs, and Calb2 (Fig. 8d, green framed boxes) is clustering with four miRNAs. All miRNAs were significantly upregulated, while the corresponding proteins were all significantly downregulated (Fig. 4f), thus implying a counterrotated expression. Two miRNAs, miR-22-3p and miR-30c-5p, target all three selected proteins, Nefl, Vamp2 and Calb2.

**miRNA dysregulation is consistent in mice and men**

To determine the functional impact of miRNA dysregulation on PD-associated protein networks, we performed an IPA-based network analysis using all 45 upregulated miRNAs and all 49 altered proteins from our defined functional groups (Fig. 9). The majority of dysregulated miRNAs were involved in the same pathways as the proteins identified in our proteome analyses, such as protein ubiquitination, calcium signaling, cell and oxidative stress, synaptic transmission, and cytoskeleton assembly. These data revealed 77 protein-miRNA interactions, involving 25 proteins and 31 miRNAs, in which the proteins were downregulated and the respective miRNAs were upregulated, as well as eight protein-protein interactions. Nefl, Calb2, and Vamp2 clustered extensively with several miRNAs. Thirty-one miRNAs from all dysregulated miRNAs in psA30P mice have been shown to be dysregulated in human PD tissues and body fluids (Supplementary Table 6a), and 13 have been implicated in PD in mouse, rat, and in vitro models (Supplementary Table 6b). However, these miRNAs were only investigated during clinical stages of PD and in the CNS, and not during pre-symptomatic stages and in the gut or MP like in the present study. In addition, we detected 10 significantly dysregulated miRNAs in the
MP of the LI in psA30P mice, which, to the best of our knowledge, have not been associated with PD to date (Supplementary Table 6c).

Discussion

PD is currently diagnosed based on motor impairments that are only present during progressive stages of the disease [69]. These clinical symptoms are caused by Lewy bodies aggregating in the brain and by degeneration of dopaminergic neurons in the substantia nigra. Up to 60–70% of these neurons are already lost when the first motor symptoms appear [70]. The gold-standard treatment for managing these motor symptoms in advanced PD is oral administration of the dopamine precursor levodopa (L-dopa). Although short-term oral use of L-dopa is highly effective, long-term use is associated with several complications [71]. Thus, early diagnosis of PD combined with an efficient prophylaxis or therapy that delays or even prevents PD is essential. However, early diagnosis is challenging because biopsies cannot be easily obtained from the brain to monitor the progression of the disease over time. Early pathological signs of PD have been reported in the ENS of patients, suggesting that neurodegeneration may start in the gut and spreads to the brain [7, 8].

Recent studies gave evidence that PD might be separated into a PNS-first and a CNS-first subtype [72, 73]. The brain-first type is associated with a primary occurrence of the α-synuclein pathology in the brain and a secondary spread to the ENS. The body-first type is
hallmarked by an initial contribution of the ENS, mostly accompanied by non-motoric symptoms, followed by a striatal dopaminergic dysfunction.

Based on this hypothesis, pathological analysis of the GI tract may detect PNS-first PD early enough to apply preventative therapies. In addition to motor impairments, bowel disturbances have been described in PD patients before clinical symptoms develop [74].

In our study we provide an assessment of ENS dysfunction early in PD pathogenesis in α-synuclein-overexpressing transgenic A30P mice, presumably mirroring the body-first PD type. To identify early biomarkers for PD within the gut, analyses were made using A30P mouse PD model, which allows an investigation of pre-symptomatic stages unlike in human patients. First we defined a pre-symptomatic (ps) stage of disease in which the mice neither exhibited any motoric impairments nor showed an imbalance of striatal dopamine levels, as it is reported to take place during the clinical peak of disease [25, 75]. When exploring the gait, psA30P mice were inconspicuous, and aside from that, they did not show reduced striatal dopamine levels [76], therefore signifying a not yet diseased brain. However, we demonstrated that these young mice have a diseased gut possessing several α-synuclein aggregates or Lewy bodies, in fact in both intestines. We propose that the ENS of α-synuclein-overexpressing transgenic A30P mice is more sensitive to A30P α-synuclein than the CNS, confirming the assumption, that the A30P mice either belong to the PNS-first PD category or that we do not yet understand that additional triggers might be responsible for the development of one or the other form of PD. The differences between the small and the large intestine may be caused by the presence of microbiota in

**Fig. 9** Ingenuity pathway analysis (IPA). IPA shows the relationships between altered miRNAs in the myenteric plexus (MP) of the large intestine (LI) from pre-symptomatic (ps)A30P mice compared with wild type (WT) controls and their target proteins. IPA functional pathway analysis was used to predict the top transcriptional regulators from differentially expressed proteins in murine PD models. miRNA target (protein) filter pairing analysis was done in order to identify co-regulated miRNAs/target pairs. We identified 77 protein-miRNA interactions which involved 25 dysregulated proteins and 31 miRNAs and eight protein-protein interactions. These predictions are based on Ingenuity Pathway Knowledge Base (IPKB). Nefl is targeted by let-7i-5p, miR-10a-5p, miR-22-3p, miR-30c-5p, miR-99a-5p, miR-125a-5p, miR-126-3p, miR-126-5p, and miR-181a-5p; Vamp2 is targeted by let-7i-5p, miR-10a-5p, miR-22-3p, miR-30c-5p, miR-99a-5p, miR-135a-5p, miR-338-3p, miR-350-3p, miR-377-3p, and miR-495-3p; Calb2 is targeted by miR-17-5p, miR-22-3p, miR-30c-5p, and miR-495-3p.
the large intestine [14, 17]. This primary interface of microbial products with the ENS may trigger a prior start in the gut and also accounts for the advanced pathology in the large intestine compared with the small intestine. Hence, 2-month-old mice were specified as pre-symptomatic featuring a typical PD pathology in the gut, but not in the brain.

A major finding of the present study is decelerated GI motility in early PD, before motoric disturbances are detected. Consistent with these findings, PD patients with chronic constipation typically exhibit infrequent bowel movements, impaired propulsive colonic motility, and prolonged colonic transit with reduced rectal contractions [74]. Impaired colonic transit has already been described in young α-synuclein-overexpressing animals [77, 78], but besides the digestion speed no additional dynamic parameters were reported. In our ex vivo approach it is also possible to ascertain more convincing parameters, like number or velocity of individual contractions or dilatations respectively, as well as intervals. Additionally, it is known from biopsies that the LI is more affected by Lewy bodies in the myenteric neurons than the SI is [79, 80], reflecting our synuclein aggregate stainings. These observations support our finding of a stronger pathological effect in the LI than in the SI.

To provide evidence that the gut and ENS are involved in PD onset, and to confirm that PD pathogenesis starts in the gut, we investigated whether these functional changes correspond to molecular or morphological abnormalities in the GI tract at this stage. Changes in protein and miRNA expression in body fluid samples and post mortem brain biopsies from PD patients have improved our understanding of PD pathology. PD-related proteins are involved in several pathways including protein ubiquitination, oxidative stress, cytoskeleton development, synaptic function and vesicle release, and calcium binding [4]. Lowe et al. discovered that the majority of Lewy bodies in the brain contains ubiquitin [50], which conjugates to other proteins to bring about protein degradation [81]. In line with this, post mortem studies have shown defective proteasome activity in PD brains [82] that involve alterations in the ubiquitin-proteasome pathway [40]. To the best of our knowledge, dysregulation of proteins that regulate ubiquitination has not been investigated in the ENS during early stages of PD. In this study, we found that the expression of proteins, responsible for protein folding and ubiquitination, was altered in the MP of the SI and the LI. Of note, these proteins were all involved in regulating the ubiquitin-proteasome pathway [83].

Oxidative stress reflects the imbalance between the production and detoxification of reactive species, involving oxygen species and nitrogen species. At the cellular level, thiol redox homeostasis is maintained by the thioredoxin/peroxiredoxin (Trx/Prdx) pathway or by glutathione peroxidase (Gpx), which is part of the glutathione (Gsh) pathway. A marker for oxidative stress in PD postmortem brains is an increased level of hydroxyl radicals, which reduces expression of neuroprotective proteins like Trx1, glutathione-S-reductase (Gsr), and Gpx [84]. Moreover, reduced expression of Prdx in the brain has been linked to neurodegenerative diseases including Alzheimer’s disease and PD [85]. We found evidences for oxidative stress in the gut during early stages of PD in the present study. Expression of neuroprotective proteins was significantly altered in the MP of psA30P mice, for instance Gpx, Prdx2, Prdx4 and Gsr. These changes coincided with significantly increased expression of several miRNAs, which are known to regulate these proteins. It is well known that increased reactive oxygen species formation leads to tissue damage and its dysfunction induced oxidizing lipids which generate highly reactive lipid peroxidation products, such as peroxides and aldehydes. Massive amounts of malondialdehyde (MDA) can be found in the substantia nigra in the postmortem brain of PD patients [86]. In several independent studies elevated levels of MDA were demonstrated in the sera and plasma of PD patients [87–91]. Here, we also illustrated increased MDA levels outside the brain, e.g. the MP of young psA30P mice displaying enhanced oxidative stress in an early non-motoric stage of disease in the gut.

These findings provide the first proof that oxidative stress markers are strikingly dysregulated in the gut during early PD, and that these proteins may represent markers of early PD.

Cytoskeletal reorganization is required for neuronal homeostasis and plasticity, and for responses to axon injury and degeneration [35]. Disrupted post-translational modifications of neurofilament proteins have been linked to neurodegenerative disorders, including PD [56, 92].

Downregulation of neurofilament miRNA and proteins is common in the brain of PD patients and PD animal models [57, 58]. In agreement with these observations, we found significantly reduced Nefl protein expression in the ENS. In addition, we observed significant upregulation of miRNAs that regulate Nefl [32, 93]. Globular and filamentous actins are highly enriched in dendritic spines and are regulated during synaptic plasticity by actin-binding proteins (ABPs) [94]. ABPs, such as profilin and the actin-related-protein 2/3 complex (Arpc4), control actin polymerization and are dysregulated in neurological brain disorders including PD [95, 96]. Here, we showed that expression of profilin and Arpc4 is markedly changed in the LI of psA30P mice, indicating neurofilament disruption in the gut during early stages of PD. Interestingly, profilin is known to cluster with several miRNAs, e.g. miR-130a-3p and 132-3p, which
were strongly upregulated in our psA30P model. Consistent with these observations, profilin expression was reduced in the MP of psA30P mice. In line with our findings, miR-132-3p expression was increased in the striatum of a symptomatic rotenone-induced PD rat model [96]. We present evidence that cytoskeletal disruption also contributes to neurodegeneration in the ENS during early stages of PD.

Dynactin is, as a part of the dynactin-dynein-complex (DDC), responsible for axonal transport, and the passage of cytoplasmic vesicles [97], and it affects α-synuclein aggregation increases Lewy body formation in different brain regions [98]. In this study, we found reduced dynactin 2 expression in the MP of psA30P mice, suggesting a reduced axonal transport of motor proteins in the gut at early stages of PD. This assumption is strengthened by upregulations of the counter-rotating miRNAs, which cluster to the DDC and regulate the same pathways [32, 99].

Different tau isoforms, like Mapt, are expressed in the CNS and ENS, but their expression is not altered in the ENS of PD patients with clinical symptoms [100]. Hallmark characteristics of prion diseases like PD are reduced synapse numbers and reduced dendritic spine densities. Boese et al. described a strong enrichment of several miRNAs including miR-136-5p, which targets Mapt, during the pre-clinical phase of prion disease [101]. Relevant to this, we report for the first time that Mapt is highly downregulated in the MP of the LI during the pre-symptomatic stage of PD. This downregulation correlated with an increased expression of miR-22-3p and miR-136-5p. Very recently, deletion of Map6, which interacts with Mapt [102] and was markedly decreased in our model, was reported to cause muscle weakness and atrophy, reduced calcium release, and alterations in the microtubule network, mirroring the early motoric impairments observed in the gut of α-synuclein-overexpressing mice [103, 104]. Interestingly, α-synuclein interacts with microtubules in HeLa cells [105] and preferably with tyrosinated tubulin in human mesencephalic neurons [106]. In agreement with our in vitro results, A30P α-synucleins regulate the microtubule network in PD. These mutated α-synucleins can affect neuronal microtubule assembly, and their overexpression leads to microtubule dysfunction and nigral neurite degeneration [107]. Our data imply that A30P α-synuclein pathology also impacts the cytoskeleton of ENS neurons during early PD.

Synaptic transmission is driven by Ca2+-dependent vesicle soluble N-ethylmaleimide-sensitive factor attachment (SNAREs), which allow synaptic vesicles to fuse to the plasma membrane [108]. Ca2+-binding synaptotagmins (Syt) interact with the SNARE proteins Vamp2, synaptaxin1 (Stx1), and synaptosomal-associated protein 25 (Snap25) for exocytosis [109]. Native α-synuclein, which is a neuronal pre-synaptic protein, is involved in the trafficking of synaptic vesicles and in vesicle exocytosis [110, 111]. However, aggregated α-synuclein is cytotoxic and mediates synaptic dysfunction by preventing the transport of synaptic proteins or the re-clustering of synaptic vesicles, resulting in a reduced neurotransmitter release [66, 112]. Misfolded α-synuclein co-localizes with Vamp2 and promotes SNARE-complex assembly [67, 113], while α-synuclein triple-knockout mice show neurological damage and reduced SNARE assembly [114]. In our study, Stx1, Syt1, and Vamp2, which are all involved in the synaptic vesicle cycle [115], were significantly downregulated in the gut of psA30P mice. This may explain the gut pathology observed in our psA30P mice supported by our findings that miRNAs clustering with Vamp2 are upregulated. This theory is also supported by the results of our in vitro experiments. Thus, the reduced expression of synaptic vesicle proteins, together with increased expression of the miRNAs that regulate them, may contribute to neuronal cell death in pre-symptomatic PD.

In addition to its important role in synaptic transmission, calcium also plays a pivotal role in neurodegeneration [116]. Intracellular Ca2+-dependent pathways dramatically increase calcium levels, which can trigger apoptotic cascades. Calcium-binding proteins (CaBPs) maintain calcium homeostasis for neuronal survival [117, 118]. CaBPs like calbindin-D (CalbD) and Calb2 are widely expressed in the CNS [119, 120] and the ENS [121–123]. Different neuronal populations have variable vulnerability to degeneration. Lack of CalbD in dopaminergic neurons increases susceptibility to PD; this is further supported by the low percentage of CalbD-positive neurons in advanced stages of PD [124]. Calb2 is expressed close to the plasma membrane and calcium channels [125], so may be involved in calcium influx, neuronal excitability, and neurotransmitter release [126, 127]. Moreover, Calb2 has been associated with other neurological disorders including schizophrenia [128]. Here, Calb2 positive neurons were paradoxically increased after acute α-synuclein exposure suggesting a temporary higher resistance of these neurons compared to other neuronal subtypes. However, a chronic exposure reduced Calb2 neurons and implicated an increase of miR-17-5p that regulates Calb2. It has been postulated, that an increase of Calb2 expression indicates neuroprotective processes in early stages of PD [68]. Hence, the increase of Calb2 in myenteric cultures might be a first reaction to A30P α-synuclein, while a reduction of Calb2 expression, as seen in whole-mount stainings of psA30P mice, resembles later stages of PD and chronic exposure to pathological A30P α-synuclein, where augmented cell death has already occurred. Furthermore, it has been reported, that an upregulation of miR-17-5p
inhibits cell proliferation and induces apoptosis, while an inhibition induces neurite outgrowth [129]. Based on these findings, we postulate that Calb2 plays a crucial role in PD development in the gut. Our hypothesis is supported by previous findings that Calb2 expression is reduced in neurons following 6-OHDA treatment in a PD rat model [66, 67].

Conclusions
In the present study we identified for the first time early functional and whole panel of molecular, gut-related biomarkers that may detect PD during early stages of the disease, long before motoric onset of the disease. Nefl, Vamp2, and Calb2, and their regulating miRNAs seem to be key players in the initiation of the disease. These proteins and miRNAs are mainly involved in cytoskeleton assembly, oxidative stress, ubiquitin-proteasome degradation, synaptic transmission, and calcium signaling, and may contribute to intestinal dysfunction during early PD. In postmortem brains and liquid biopsies from PD patients, which are derived from a very late clinical stage of the disease, markers like PINK1, Parkin, DJ1, and LRRK2 are dysregulated [130–132]. Hence, these are rather more suitable markers for later stages of the disease in the CNS. In the future, the ENS may serve as a source for minimally invasive gut biopsies for early detection of PD, which can be taken easily from human patients. Therefore, our novel biomarkers may open up the possibility of screening gut tissue to diagnose PD during its early stages, which may facilitate the timely treatment or even prevention of PD.

Abbreviations

α30P: α-synuclein; aggregated A30P α-synuclein; ABP: Actin-binding protein; mA30P: α-synuclein: monomeric A30P α-synuclein; Arpc4: Actin-related-protein 2/3 complex; BOS: Base of support; Calb2: Calcium-binding proteins; Calb2: Calbindin 2; CalbD: Calbindin-D; CNS: Central nervous system; CO: Control; DDC: Dynactin-dynein-complex; ENS: Enteric nervous system; Gl: Gastrointestinal; Gpx: Glutathione peroxidase; Gsh: Glutathione; Gsr: Glutathione-S-reductase; hu-synuclein: human synuclein; L: Left forepaw; LH: Left hindpaw; L: Large intestine; Map 6: Microtubule-associated protein 6; Mapt: Microtubule associated protein tau; MDA: malondialdehyde; miRNA: MicroRNA; MP: Myenteric plexus; Nefl: Neurofilament light chain; 6; Mapt: Microtubule associated protein tau; MDA: malondialdehyde; miRNA: MicroRNA; MP: Myenteric plexus; Nefl: Neurofilament light chain; PD: Parkinson’s disease; PGP 9.5: Protein gene product 9.5; Prx: Peroxiredoxin; psA30P: Pre-symptomatic A30P α-synuclein mouse; RF: Right forepaw; RH: Right hindpaw; Sl: Small intestine; Snap25: Synaptosomal-associated protein 25; SNARE: Vesicle soluble N-ethylmaleimide-sensitive factor attachment; Sx1: Synaptaxin1; Syt: Synaptotagmin; Tx: Thioreredoxin; Tuj1: class III beta tubulin; Vamp2: Vesicle-associated membrane protein 2; WT: Wild type

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13244-02-00439-2.

Supplementary Figure 5. Ganglionic areas in pre-symptomatic (ps)A30P and wild type (WT) mice. Supplementary Figure 6. Acute treatment of enteric cells with aggregated A30P α-synuclein. Supplementary Figure 7. Top ten regulated miRNAs in the myenteric plexus (MP) of the large intestine (LI) in pre-symptomatic (ps)A30P mice and wild type (WT) mice. Supplementary Table 1. Primary and secondary antibodies used and respective dilutions and applications. Supplementary Table 2. Protein expression profile in the myenteric plexus (MP) of the small intestine (Sl) and the large intestine (L) in pre-symptomatic (ps)A30P and wild type (WT) mice detected by mass spectroscopy. Supplementary Table 3. nCounter Mouse v1.5 miRNA Gene List. Supplementary Table 4. Expressed miRNAs in the mesencephalon of pre-symptomatic (ps)A30P and wild type (WT) mice. Supplementary Table 5. Expressed miRNAs in the myenteric plexus (MP) of the large intestine (LI) in pre-symptomatic (ps)A30P and wild type (WT) mice. Supplementary Table 6. Dysregulated miRNAs in different tissues and their correlation to Parkinson’s disease (PD) models and patients. Supplementary Table 7. List of Cohen’s d effect size [34] calculations.

Additional file 2: Supplementary video 1. Motility recordings during luminal perfusion of the small intestine in 2-month-old wild type mice.

Additional file 3: Supplementary video 2. Motility recordings during luminal perfusion of the small intestine in 2-month-old pre-symptomatic A30P mice.

Additional file 4: Supplementary video 3. Motility recordings during luminal perfusion of the large intestine in 2-month-old wild type mice.

Additional file 5: Supplementary video 4. Motility recordings during luminal perfusion of the large intestine in 2-month-old pre-symptomatic A30P mice.

Acknowledgements

The authors thank Tobias Fritz for technical support with the CatWalk XT System, which was performed at the Saarland University, Homburg. We thank Salam Warda for analyzing the motility videos, David Grundmann and Alexandra Conrad for the help with the myenteric plexus isolation used for the proteomics. We thank Liz Spycher for technical assistance.

Authors’ contributions

Manuela Gries, Anne Christmann and Karl-Herbert Schäfer conceived the project, designed and supervised all experiments, analyzed and interpreted results and wrote the manuscript. Steven Schulte helped generating and analyzing all immunohistochemical data, with the sample preparations, dopamine ELISA and writing. Maximilian Weyland assisted with heatmap establishment and sample preparations. We thank Marko Baller for statistical support and writing the commercial LabView software. Ralph Röth, Stefanie Schmitteckert, Beate Niesler and Gundrun A. Rappold performed the nCounter expression profile studies and helped with pathway design, analyses and comparisons. Marcus Unger supported in clinically associated PD questions. Monika Martin und Stephanie Rommel assisted with sample preparation. Yang Liu and Markus Britschgi kindly provided the Thy1-SNCA-A30P mice. Michael Schorda, Frederik Sommer and Timo Mühlhaus made the mass spectrometric experiments. Jean-Pierre Timmermans and Isabel Pintelon generated the three-dimensional images. Hilal Lashuel maintained synuclein related issues and kindly provided the A35P α-synuclein. Michael D. Menger and Matthias W. Laschke provided the CatWalk XT System. All authors discussed the results and commented on the manuscript. The author(s) read and approved the final manuscript.

Funding

This work is partly supported by the Ministry of Education and Research (BMBF, OD Pfalz: 03IHS075A) and a grant from the Deutsche Forschungsgemeinschaft (DFG SCHA/11–1). Open Access funding enabled and organized by Projekt DEAL.

Availability of data and materials

Raw images and datasets that support the findings of this study are available from the corresponding author upon reasonable request.
Declarations

Competing interests
Markus Britschgi is a full-time employee at Roche and may additionally hold Roche stock/stock options.

Author details
1 Department of Informatics and Microsystems and Technology, University of Applied Science Kaiserslautern, Working Group Enteric Nervous System, 66482 Zweibrücken, Germany. 2 Department of Human Molecular Genetics, University of Heidelberg, 69120 Heidelberg, Germany. 3 Department of Neurology, Saarland University, 66421 Homburg, Germany. 4 Molecular Biotechnology and Systems Biology, University of Kaiserslautern, 66763 Kaiserslautern, Germany. 5 Computer Systems Biology, University of Kaiserslautern, 66763 Kaiserslautern, Germany. 6 Laboratory of Cell Biology and Histology, Department of Veterinary Sciences, University of Antwerp, 2610 Antwerp, Belgium. 7 Interdisciplinary Center of Neuroscience, 69120 Neuroscience Discovery, Roche Innovation Center Basel, 4070 Basel, Switzerland. 8 Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, École Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland. 9 Institute for Clinical & Experimental Surgery, Faculty of Medicine, Saarland University, 66421 Homburg, Germany. 10 Department of Pediatric Surgery, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.

Received: 25 September 2020 Accepted: 3 March 2021

Published online: 02 June 2021

References
1. Postuma RB, Deng D, Stem M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–601.
2. Cersosimo MG, Raina GB, Pecci C, Pellene A, Calandra CR, Gutiérrez C, et al. Evidence for bidirectional and trans-synaptic parasympathetic and specific gut dysfunction specifically in aged mice. Nat Neurosci. 2020;23(3):327–34.
3. Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. α-synuclein in Lewy bodies. Nature. 1997;388(6645):839–40.
4. Fernandez DG, Reed X, Singleton AB. Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. J Neurochem. 2016;139(1 Suppl 1):S59–74.
5. Biaik H, De Vos RAI, Bohl J, Del Tredici K. Gastric α-synuclein immunoreactive inclusions in Meisner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett. 2006;396(1):67–72.
6. Leboucq T, Chaumette T, Damier P, Coron E, Toucheufy Y, Vignaud S, et al. Pathological lesions in colonic biopsies during Parkinson’s disease. Gut. 2008;57(12):1741–3.
7. Biaik H, Rüg U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neurol Transm (Vienna). 2003;110(5):37–36.
8. Biaik H, Del Tredici K, Rüg U, De Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211.
9. Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Bjorklund T, et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. 2014;128(6):605–20.
10. Chalich C, Horst A, Sampson TR, Yoo BB, Chalis RC, Hamilton AM, et al. Gut-seeded α-synuclein fibres promote gut dysfunction and brain pathology specifically in aged mice. Nat Neurosci. 2020;23(3):327–336.
11. Van Den Berge N, Ferreira N, Gram H, Mikkelsen TW, Alstrup AKO, Casadei N, et al. Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats. Acta Neuropathol. 2019;138:535–50. https://doi.org/10.1007/s00401-019-02040-w.
12. Kim S, Kwon S, Kim T, Panicker N, Karuppagounder S, Lee S, et al. HHS Public Access. 2020;103:627–41.
13. Scheperjans F, Aho V, Pereira PAB, Koskinen K, Paulin L, Pekkonen E, et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord. 2015;30(3):350–8.

14. Unger MM, Spiegel J, Dillmann KU, Grundmann D, Philippert H, Bürmann J, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Park Relat Disord. 2016;32:662–72.
15. Endres K, Schäfer KH. Influence of commensal microbiota on the enteric nervous system and its role in neurodegenerative diseases. J Innate Immun. 2018;10(3):172–180.
16. Seguella L, Samelli G, Esposito G. Leaky gut, dysbiosis, and enteric glia activation: the trilogy behind the intestinal origin of Parkinson’s disease. Neural Regen Res. 2020;15(6):1037–8.
17. Schwierz A, Spiegel J, Dillmann U, Grundmann D, Bürmann J, Falb-Bender K, et al. Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson’s disease. Park Relat Disord. 2018;50:104–7.
18. Zibert JR, Lavendorf MB, Utman T, Olsen J, Kazickowski B, Skov L. MicroRNAs and potential target interactions in psoriasis. J Dermatol Sci. 2018;83(1):177–85.
19. Mitchell PS, Pankin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513–8.
20. Gwiggner M, Martinez-Nunez RT, Whitesol SR, Bondanese VP, Clardique A, Collins JE, et al. MicroRNA-31 and MicroRNA-155 are overexpressed in ulcerative colitis and regulate IL-13 signaling by targeting intereleukin 13 receptor α-1. Genes (Basel). 2018;9(2):85.
21. Dias V, Jami E, Mouradian MM. The role of oxidative stress in Parkinson’s disease. J Parkinsons Dis. 2013;3(4):461–91.
22. de Guire V, Robitaille R, Tretiault N, Guélin R, Ménard C, Bancace B, et al. Circulating miRNAs as sensitive and specific biomarkers for the diagnosis and monitoring of human diseases: promises and challenges. Clin Biochem. 2013;46(10–11):846–60.
23. Mustagh G, Heigl N, Anwar F, A. Zamzami M, Choudhry H, M. Shaik M, et al. miRNAs as Circulating Biomarkers for Alzheimer’s Disease and Parkinson’s Disease. Med Chem (Los Angeles). 2016;12(3):217–25.
24. Chen L, Yang J, Li J, Cao S, Zhao Q, Yu Z. Identification of aberrant circulating miRNAs in Parkinson’s disease plasma samples. Brain Behav. 2018;8(6):e00941.
25. Kahej PJ, Neumann M, Ozenm L, Müller V, Jacobsen H, SCHINDZIELER A, et al. Subcellular localization of wild-type and Parkinson’s disease-associated mutant α-synuclein in human and transgenic mouse brain. J Neurosci. 2000;20(17):6365–73.
26. Schäfer KH, Saffrey MJ, Burnstock G, Mestres-Ventura P. A new method for the isolation of myenteric plexus from the newborn rat gastrointestinal tract. Brain Res Protoc. 1997;12(1):109–13.
27. Grundmann D, Klott M, Rabe H, Glanemann M, Schäfer KH. Isolation of high-purity myenteric plexus from adult human and mouse gastrointestinal tract. Sci Rep. 2015;5:2926.
28. Kreyeider D, Jost V, Bischof M, Seebach K, Lammers WJ e, et al. Morphology of ex vivo enteric intestine segments depend on perfusion mode. World J Gastroenterol. 2014;20(48):18216–27.
29. Mühlhaus T, Weiss J, Hemme D, Sommer F, Schrda M. Quantitative shotgun proteomics using a uniform 15N-labeled standard to monitor proteome dynamics in time course experiments reveals new insights into the heat stress response of Chlamydomonas reinhardti. Mol Cell Proteomics. 2011;10:1–27.
30. Bossonali GDP, Pintelon J, Detrez JD, Buckin R, Thys S, Zanoni JN, et al. Comparative analysis reveals Ce3D as optimal clearing method for in toto imaging of the mouse intestine. Neurogastroenterol Motil. 2019;31(5):e13560.
31. Follmer C, Romão L, Einsiedler CM, Porto TC, Lara FA, Monares M, et al. Dopamine affects the stability, hydration, and packing of protofibrils and fibrils of the wild type and variants of α-synuclein. Biochemistry. 2007;46(2):472–82.
32. Stich C, De La Torre C, Parveen A, Grett N, Minwalk A. An online resource for prediction of mircoRNA binding sites. PLoS One. 2018;13(10):e0206239.
33. Cohen J. 2.2. The effect size index d: In: Statistical Power Analysis for the Behavioral Sciences. 1988.
34. Pasquini M, Giolus M, Sanson F de, Giovanni L, Filippi G, Rosetto F, et al. Gait analysis and clinical correlations in early Parkinson’s disease. Funct Neurorol. 2017;32(1):28–34.
35. Muñoz-Lasso DC, Romá-Mateo C, Pallarés FV, Gonzalez-Cabo P. Much more than a scaffold: cytoskeletal proteins in neurological disorders. Cells. 2020;9(2):358.
36. Bott CJ, Winkcker B. Intermediate filaments in developing neurons: beyond structure. Cytoskeleton. 2020;77(3):410–128.

37. Muddapu VR, Dharshini SAP, Chakravarty VS, Gromiha MM. Neurodegenerative diseases – is metabolic deficiency the root cause? Front In Neuosci. 2020;14:213.

38. Bader Y, Winkloher BF, PINK1 and Parkin: team players in stress-induced mitophagy. Biochim. Biophys. Acta. 2020;2040(5–6):789–819.

39. Oliveira LOD, da Silva PIC, Filho RR, Progénio RCS, de Oliveira VPDS, Silva RC, et al. Prior exercise protects against oxidative stress and motor deficit in a rat model of Parkinson’s disease. Metab Brain Dis. 2020;35(1):175–81.

40. Lim KL, Tan JMM. Role of the ubiquitin proteasome system in Parkinson’s disease. BMC Chem. 2007;8 Suppl 1(Suppl 1):515.

41. Ji T, Zhang X, Xin Z, Xu B, Jin Z, Wu J, et al. Does perturbation in the mitochondrial protein folding pave the way for neurodegeneration diseases? Ageing Res Rev. 2020;57:100977.

42. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. Mitochondrial import and accumulation of α-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem. 2008;283(14):9089–100.

43. Petrynyz S, Parent A, Parent M. The calretinin interneurons of the striatum: comparisons between rodents and primates under normal and pathological conditions. J Neural Transm. 2018;125(3):279–90.

44. Haberman A, Williamson WR, Epstein D, Wang D, Rina S, Meinertzhagen IA, et al. The synaptic vesicle SNARE neuronal synaptobrevin promotes endolysosomal degradation and prevents neurodegeneration. J Cell Biol. 2012;196(2):285–96.

45. Choi BK, Choi MG, Kim JY, Yang Y, Kweon DH, Gil JW, et al. Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc Natl Acad Sci USA. 2013;110(10):4087–92.

46. Soukup S, Vanhauwaert R, Verstreken P. Parkinson’s disease: convergence on synaptic homeostasis. EMBO J. 2018;37(18):e98960.

47. Pellegrini C, Ippolito C, Segnani C, Dolfi A, Errede M, Virgintino D, et al. Gliarial calretinin protect dopaminergic neurons against degeneration in a rat model of Parkinson disease. Brain. 2019;142(4):686–92.

48. Ji T, Zhang X, Xin Z, Xu B, Jin Z, Wu J, et al. Does perturbation in the mitochondrial protein folding pave the way for neurodegeneration diseases? Ageing Res Rev. 2020;57:100977.

49. Langston J, Ballard P, Tetrud J, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219(4587):979–81.

50. Lowey J, Blanchard A, Morell K, Lennox G, Reynolds L, Billet M, et al. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson’s disease, Pick’s disease, and Alzheimer’s disease, as well as Rosenthal fibres in cerebellar astrocytomias, cyttoplasmic bodies in m. J Pathol. 1988;155(1):9–15.

51. Mayer R, Loughran J, Lennox G, Doherty F, Landon M. Intermediate filaments and ubiquitin: a new thread in the understanding of chronic neurodegenerative diseases. Prog Clin Biol Res. 1989;317:809–18.

52. Przedsiborski S, Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov Disord. 1998;13 Suppl 1:35.

53. Cappelletti G, Maggioni MG, Maci R. Influence of MPP+ on the state of tubulin polymerisation in NGF- differentiated PC12 cells. J Neurosci Res. 1999;56(1):29–35.

54. Federico A, Cardiello E, Da Pozzo P, Formichi P, Gallucci GN, Radi E. Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci. 2012;322(1–2):254–62.

55. Rahman AA, Morrison BE. Contributions of VPS35 mutations to Parkinson’s disease. Neuroscience. 2019;401(15):1044–53.

56. Li J, Sun Y, Chen J. Transcriptome sequencing in a 6-hydroxydopamine rat model of Parkinson’s disease. Genes Genet Syst. 2019;94(2):161–9.

57. Ya Y, Zhan M, OuYang L, Li Y, Chen S, Wu J, et al. The effects of unilateral 6-OHDA lesion in medial forebrain bundle on the motor, cognitive dysfunctions and vulnerability of different striatal interneuron types in rats. Behav Brain Res. 2014;266:37–45.

58. Mura A, Feldon J, Mintz M. The expression of the calcium binding protein calretinin in the rat striatum: effects of dopamine depletion and L-DOPA treatment. Exp Neurol. 2000;164(2):322–32.

59. Trojanowski JQ, Lee VMY. Aggregation of neurofilament and α-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol. 1998;55(2):151–2.

60. Chen QQ, Haikal C, Li W, Li MT, Wang ZY, Li JY. Age-dependent alpha-synuclein accumulation and aggregation in the colon of a transgenic mouse model of Parkinson’s disease. Transl Neurodegener. 2018;7:13.

61. Gaugler MN, Genc O, Bobela W, Mohanna S, Arda HMT, El-Agnal OM, et al. Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Acta Neuropathol. 2012;123(5):653–69.

62. Nemani VM, Lu W, Bege V, Nakamura K, Ono B, Lee MK, et al. Increased expression of α-synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis. Neuron. 2010;65(1):66–79.

63. Choi MG, Kim MJ, Kim DG, Yu R, Jang YN, Oh WJ. Sequestration of synaptic proteins by alpha-synuclein aggregates leading to neurotoxicity is inhibited by small peptide. Plos One. 2011;6(10):e26539.

64. Mouatt-Priegent A, Agid Y, Hirsch EC. Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson’s disease? Brain Res. 1994;668:62–70.

65. Brognara L, Palumbo P, Grimm B, Palmerini L. Assessing gait in Parkinson’s disease using wearable motion sensors: a systematic review. Diseases. 2019; 8(1):18.

66. Lang AE, Lozano AM. Parkinson’s disease. First of two parts. N Engl J Med. 1998;339(15):1044–53.

67. Mulroy E, Bhatia KP. The Gut Microbiome: A Therapeutically Targetable Site of Peripheral Levodopa Metabolism. Mov Disord Clin Pract. 2019; 6(7):547–8.

68. Bonghamper P, Van Den Berge N. Brain-first versus gut-first Parkinson’s disease: a hypothesis. J Parkinsons Dis. 2019;9:S281–95.

69. Horsager J, Andersen KB, Knudsen K, Skjærbæk C, Fedorova TD, Okkels N, et al. Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study. Brain. 2020;43:3077–88.

70. Lang AE, Lozano AM. Parkinson’s disease. First of two parts. N Engl J Med. 1998;339(15):1044–53.

71. Miltroy E, Bhatia KP. The Gut Microbiome: A Therapeutically Targetable Site of Peripheral Levodopa Metabolism. Mov Disord Clin Pract. 2019; 6(7):547–8.

72. Przedsiborski S, Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov Disord. 1998;13 Suppl 1:35–8.

73. Cappelletti G, Maggioni MG, Maci R. Influence of MPP+ on the state of tubulin polymerisation in NFG- differentiated PC12 cells. J Neurosci Res. 1999;56(1):29–35.

74. Federico A, Cardiello E, Da Pozzo P, Formichi P, Gallucci GN, Radi E. Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci. 2012; 322(1–2):254–62.

75. Rahman AA, Morrison BE. Contributions of VPS35 mutations to Parkinson’s disease. Neuroscience. 2019;401(15):1044–53.

76. Conde MA, Alza NP, Iglesias González PA, Scodellaro Bilbao PG, Sánchez Campos S, Urraia RM, et al. Phospholipase D1 downregulation by α-synuclein: implications for neurodegeneration in Parkinson’s disease. Biochim Biophys Acta - Mol Cell Biol Lipids. 2018;1863(6):639–50.

77. Hill WD, Arai M, Cohen JA, Trojanowski JQ. Neurofilament mRNA is reduced in Parkinson’s disease substantia nigra pars compacta neurons. J Comp Neurol. 1993;329(12):3695–708.

78. Zhang XM, Anwar S, Kim Y, Brown J, Comte I, Cai H, et al. The A30P α-synuclein mutation decreases subventricular zone proliferation. Hum Mol Genet. 2019;28(14):2283–94.
84. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, et al. Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol. 1994;36(3):348–55.

85. Jian W, Wei X, Chen L, Wang Z, Sun Y, Zhu S, et al. Inhibition of HDAC6 increases acetylation of peroxiredoxin1/2 and ameliorates 6-OHDA induced dopaminergic injury. Neurosci Lett. 2017;658:114–20.

86. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, et al. Basal lipid peroxidation in Substantia Nigra is increased in Parkinson’s disease. J Neurochem. 1989;52:381–9.

87. Nadauthoma RM, Bharath RD, Jhunjhunwala K, Yadav R, Saini J, Christopher R, et al. Imaging biomarker correlates with oxidative stress in Parkinson’s disease. Neurol India. 2017;65:263–8.

88. Kilinc A, Yalçin AS, Yalçin D, Taga Y, Emerk K. Increased erythrocyte ceramide levels in Parkinson’s disease. Clin Biochem. 2016;49:103–9.

89. Kalra J, Rajput AH, Mantha SV, Chaudhary AK, Prasad K. Oxygen free radical producing activity of polymorphonuclear leukocytes in patients with Parkinson’s disease. Mol Cell Biochem. 1992;121:181–6.

90. Mythri RB, Venkateshappa A, Harish G, Mahadevan A, Muthane UB, Yasha F, et al. Ceramide is involved in Lewy body pathology. Neuropathology. 2018;38(6):583–92.

91. Antal M, Freund TF, Polgár E. Calcium-binding proteins, parvalbumin- and calbindin-28k-immunoreactive neurons in the rat spinal cord and dorsal root ganglia: a light and electron microscopic study. J Comp Neurol. 1990;295(3):467–84.

92. Foo KS, Hellysaz A, Broberger C. Expression and colocalization patterns of calbindin-D28k in the rat hypothalamic arcuate nucleus. J Chem Neuroanat. 2014;61:295(3):467–80. https://doi.org/10.1016/j.jchennaw.2014.03.007.

93. Krämer A, Green J, Pollard J, Tugendreich S. Causal analysis approaches in systems biology. Brief Bioinform. 2015;16(2):241–53.

94. Welch MD, Iwamatsu A, Mitchison TJ. Actin polymerization is induced by Arp2/3 protein complex at the surface of listeria monocytogenes. Nature. 1997;385(6613):265–9.

95. Fairless R, Willers SM, De Michele G, Bonifati V. The EF-hand family of calcium-mobilized proteins. Trends Neurosci. 1989;12(11):462–7.

96. Foos BC, Hellysaz A, Broberger C. Expression and colocalization patterns of calbindin-D28k, calbindin and parvalbumin in the rat hypothalamic arcuate nucleus. J Chem Neuroanat. 2014;61:295(3):467–80.

97. Gries S, da Silva Ribeiro CY, et al. Signature of Aberrantly Expressed microRNAs in Parkinson’s disease. Cytoskeleton. 2016;73(9):477–85.

98. Kuo YM, Li Z, Jiao Y, Gaborit N, Pani AK, Orrison BM, et al. Extensive enteric neural network abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated a-synuclein gene mutations precede central nervous system changes. Hum Mol Genet. 2010;19(9):1633–50.

99. Timmermans JP, Adriaenssen D, Comelissen W, Scheuermann DW. Structural organization and neuropeptide distribution in the mammalian enteric nervous system, with special attention to those components involved in mucosal reflexes. Comp Biochem Physiol A Physiol. 1997;118(2):331–40.

100. Kiss E, Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson’s disease? Ann Neurol. 1992;32:Suppl:88–93.

101. Barbiroli A, Santambrogio C, Ragg EM, Casagrande FVM, et al. a-Synuclein is a Novel Microtubule Dynamase. Sci Rep. 2016;6:33289.

102. Calogero AM, Mazzetti S, Pezzoli G, Cappelletti G. Neuronal microtubules and proteins linked to Parkinson’s disease: a relevant interaction? Biol Chem. 2019;400(9):1099–112.

103. McNew JA, Parlati F, Fukuda R, Johnston RJ, Pakz K, Paunmer F, et al. Compartmental specificity of cellular membrane fusion encoded in SNAPRE proteins. Nature. 2000;407(6801):153–9.

104. Littletont JT, Chapman MR, Kreber R, Garment MB, Carlson SD, Ganetzky B. Temperature-sensitive paralytic mutations demonstrate that synaptic exocytosis requires SNARE complex assembly and disassembly. Neuron. 1998;21(2):401–13.

105. Murphy DD, Rueter SM, Trojanowsk JQ, Lee VMY. Synucleins are developmentally expressed, and a-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci. 2000;20(9):3214–20.

106. Cartelli D, Aliverti A, Barbiroli A, Santambrogio C, Ragg EM, Casagrande FVM, et al. Synuclein is a Novel Microtubule Dynamase. Sci Rep. 2016;6:33289.

107. Gries S, da Silva Ribeiro CY, et al. Signature of Aberrantly Expressed microRNAs in Parkinson’s disease. Cytoskeleton. 2016;73(9):477–85.
131. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MMK, Harvey K, Gispert S, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. 2004;304(5674):1158–60.

132. Di Fonzo A, Rohé CF, Ferreira J, Chien HF, Vacca L, Stocchi F, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet. 2005;365(9457):412–5

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.